desentum
Espoo, FI · Founded 2011 · 14 employees on LinkedIn · 1 known investors
Find your way into desentum
77 people in our graph share verified history with the desentum team — schools, employers, funds. One of them is your warm intro.
Ralf Wahlstenunlockedknows Pekka Mattila · together at Teknillinen korkeakoulu-Tekniska högskolan (overlapped)
knows the team · via desentum
knows the team · via Herantis Pharma
×9knows the team · via Teknillinen korkeakoulu-Tekniska högskolan
Desentum is a clinical-stage biopharmaceutical company developing allergen immunotherapy products that reprogram immune responses to allergens toward tolerance. The company targets both respiratory and food allergies, with its lead asset currently in phase II clinical trials.
Founders & leadership
desentum was founded in 2011 by Juha Rouvinen and Kristiina Takkinen.
JR
Juha RouvinenCo-founder
KT
Kristiina TakkinenCo-founder
PM
Pekka MattilainCEOPekka Mattila founded Finnzymes Group in 1987, serving as its CEO until 2010, and later held a site leadership role at Thermo Fisher Scientific. He holds a background in biochemistry and molecular biology from Helsinki University of Technology, where he worked as a research group leader in the chemistry department.
Board
HS
Hans SöderlundChairman of the Board
Investors · 1
Frequently asked questions
- What does desentum do?
- Desentum is a clinical-stage biopharmaceutical company developing allergen immunotherapy products that reprogram immune responses to allergens toward tolerance. The company targets both respiratory and food allergies, with its lead asset currently in phase II clinical trials.
- Who founded desentum?
- desentum was founded by Juha Rouvinen, Kristiina Takkinen in 2011.
- Who are desentum's investors?
- desentum's investors include Voima Ventures.
- Where is desentum headquartered?
- desentum is headquartered in Espoo, FI.